Hua Jiang

This paper develops TGF-β agonists targeting specific T and B cells to selectively suppress pathogenic immune responses in autoimmune and inflammatory diseases.

A fully orthogonal IL-2 receptor platform isolates 36 cytokine receptors in T cells; receptor-specific STAT combinations specify distinct fates, and STAT3-dominant programs give curative antitumor responses.

The paper uses synthetic cytokine receptor pairings to generate novel T cell states with distinct functions, revealing how pairing orientation and STAT combinatorics influence cell fate.

Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.

The paper shows that T cells engineered with IL-9R have better tissue infiltration, stemness, and anti-tumor activity compared to those with an orthogonal IL-9 receptor, due to stronger and more specific JAK/STAT signaling.